Akcea Therapeutics, Inc. IPO Research Information

Akcea Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Akcea Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Akcea Therapeutics, Inc.	AKCA - NASDAQ	$12.00-$14.00	$8.00	$8.13	15.63 million	7/14/2017
Underwriter(s): Cowen and Company, Stifel, Wells Fargo Securities
Co-Manager(s): BMO Capital Markets
Industry: Health Care
Filing(s): Filed 2017-03-27 Underwriter Added 2017-05-09 Terms Added 2017-06-20

Akcea Therapeutics, Inc. Quote & Chart - Click for current quote - AKCA

About Akcea Therapeutics, Inc. (adapted from Akcea Therapeutics, Inc. prospectus):
They are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AKCA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.